The role of long noncoding RNA FOXF1-AS1 as a tumor suppressor in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases and is the leading cause of cancer-related death in the United States (1). A significant challenge associated with NSCLC treatment is the lack of early diagnostic tools, as more than 70% of NSCLC patients are diagnosed at advanced stages, rendering them ineligible for surgical resection (2). Advanced-stage NSCLCs are generally treated by platinum-based chemotherapy or radiation therapy, but both treatments are highly invasive with low specificity and high recurrence rate (3-5).